NasdaqCM:LQDAPharmaceuticals
Liquidia (LQDA) Is Up 14.2% After YUTREPIA Drives Strong Q4 Sales And Cash Flow
Liquidia recently reported preliminary 2025 results showing strong uptake of its newly launched pulmonary hypertension drug YUTREPIA, with over 2,800 unique patient prescriptions and US$148.30 million in net product sales, including US$90.10 million in the fourth quarter alone.
An interesting angle for investors is that YUTREPIA’s performance has already generated over US$30.00 million in positive fourth-quarter cash flow, giving Liquidia additional financial flexibility to expand its...